Introduction and Objective: This study aimed to explore the mechanism of the dual GCGR/GLP-1R agonist mazdutide for improving liver fat accumulation compared to the GLP-1R agonist semaglutide.Methods: Mazdutide (30 nmol/kg per week) or semaglutide (30 nmol/kg every other day) was administrated subcutaneously for 8 weeks in diet-induced obesity mice to maintain a comparable level of […]
Read MoreCategory: Diabetes
1239-P: Timing of Adult Transition on Outcomes for Pregnant Young Adults with Type 1 Diabetes
Introduction and Objective: Young adults with type 1 diabetes (T1D) have higher glycemia than other age groups, yet in this time of childbearing potential there are limited data on how the transition to adult care impacts gestational outcomes.Methods: Retrospective chart review at the Barbara Davis Center for Diabetes between 2014 and 2020 of women with […]
Read More775-P: Mazdutide, a Dual GLP-1R/GCGR Agonist, Reduces Hyperuricemia by Modulating Energy and Lipid Metabolism and Inhibiting Hepatic Purine Metabolism
Introduction and Objective: Mazdutide (IBI362) is a dual agonist of GLP-1R and GCGR. Previous studies indicated that it significantly reduces serum uric acid levels in hyperuricemic rats compared to semaglutide. This study aims to further clarify the mechanism by which Mazdutide lowers uric acid in these rats.Methods: A hyperuricemia model was established in SD rats […]
Read More1355-P: Encounter Biases Using Electronic Health Records to Identify Type 2 Diabetes Incidence
Introduction and Objective: The use of electronic health records (EHR) to identify incident conditions in observational studies is growing. Health care encounters are related to health status and possibly other unobserved characteristics, which can lead to a phenomenon termed “encounter bias”. Several prior studies discussed potential encounter bias between encounter types and outcomes such as […]
Read More774-P: Robust Antiobesity Effect and Mechanistic Insights of HM15275, a Novel Long-Acting GLP-1/GIP/Glucagon Triple Agonist in Animal Model of Obesity
Introduction and Objective: Obesity has reached epidemic proportions globally, posing a critical public health crisis. To address this, HM15275, a novel long-acting GLP-1/GIP/Glucagon triple agonist was developed, demonstrating potent weight loss and glycemic control in prior preclinical studies. The present study further investigates the effects of HM15275 on body weight and body composition over an […]
Read More205-OR: Adhesion-Related Macrophages Regulates Metabolic Homeostasis through Cav-1 Dependency
Introduction and Objective: The significance of adipose tissue macrophages (ATMs) in regulating adipose tissue function is well-established. However, our investigation revealed a previously overlooked subpopulation of macrophages adhered to adipocytes, which we term adhesion-related macrophages (ARMs).Methods: We developed a method to isolate both ARMs and non-ARMs. Molecular and functional differences were analyzed, and Cav-1 knockout […]
Read More773-P: Effect of Glucagon-Like Peptide 1 Receptor Agonists Compared with Basal Insulin in Severely Uncontrolled Type 2 Diabetes
Introduction and Objective: Glucagon-like Peptide-1 receptor agonists (GLP1s) are comparable to insulin for the treatment of T2D and promote weight loss. There are limited data to guide GLP1 use in severely uncontrolled T2D (A1C ≥10%).Methods: We conducted a retrospective cohort study of 1,518 adults with T2D who were ordered a GLP1 or basal insulin within […]
Read More2101-LB: Recruitment Strategies to Increase the Reach of the National Diabetes Prevention Program in Rural Populations
Introduction and Objective: Despite a higher prevalence of prediabetes, the reach of the National Diabetes Prevention Program (DPP) has been challenging in rural areas. This study examines the preliminary utility of different recruitment strategies to improve proportion and representativeness (i.e., reach) of rural participants that enroll in the National DPP.Methods: Two Cooperative Extension sites in […]
Read More772-P: Cognitive Outcomes in Adults Treated with GLP-1 Receptor Agonists Compared with Nonusers—A Retrospective Chart Review
Introduction and Objective: GLP-1 receptor agonists (GLP-1 RAs) are recognized for glycemic and metabolic benefits in type 2 diabetes and obesity. Emerging evidence suggests neuroprotective effects via GLP-1 receptor expression in key brain regions. This study evaluated whether GLP-1 RA therapy is associated with measurable changes in cognitive function via MMSE.Methods: This retrospective cohort study […]
Read More526-P: A Patient and Health Care Professional Codesigned Diabetic Ketoacidosis Educational Infographic for Type 1 Diabetes
Introduction and Objective: Diabetic Ketoacidosis (DKA) prevention protocols are underused and difficult to understand by patients. We aimed to co-create with people living with T1D, caregivers, and healthcare professionals a core DKA education infographic.Methods: Focus groups were recruited through purposive sampling. In a user-centered design process involving oversight by a User Advisory Panel, participants were […]
Read More